文献速递胸部肿瘤放疗

局部晚期非小细胞肺癌同步放化疗前原发肿瘤立体定向体部放疗加量的2期试验

A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-02-20

该2期试验在局部晚期非小细胞肺癌患者中,于同步放化疗前对原发肿瘤行2次立体定向体部放疗加量(中央型12 Gy、周围型16 Gy),随后标准同步放化疗60 Gy/30次。主要终点1年原发肿瘤控制率为100%,达到≥90%的预设假设;仅1例4级非血液学毒性,无5级毒性。

要点

  • 同步放化疗前原发肿瘤SBRT加量(中央型12 Gy/2次、周围型16 Gy/2次)后标准同步放化疗60 Gy/30次。
  • 1年原发肿瘤控制率100%,2年92.3%;2年区域控制率81.6%、远处控制率70.3%。
  • 仅1例治疗相关4级非血液学毒性(呼吸衰竭/放射性肺炎),无5级毒性。

核心结论

  • 原发肿瘤 upfront SBRT 加量似乎可行且安全,原发肿瘤控制率高,其他肿瘤学终点与标准治疗相比有利。

研究设计与样本

  • 2期试验,纳入21例局部晚期非小细胞肺癌患者(10例男性、11例女性),中位年龄62岁(范围52-78岁)。
  • 干预为原发肿瘤SBRT加量2次(中央型12 Gy、周围型16 Gy),随后标准同步放化疗60 Gy/30次。
  • 主要终点为1年原发肿瘤控制率,假设≥90%;次要终点包括客观缓解率、区域和远处控制、无病生存和总生存。

主要发现

  • 中位治疗前原发肿瘤大小为5.0 cm(范围1.0-8.3 cm)。
  • 3个月和6个月客观缓解率分别为72.7%和80.0%;1年和2年原发肿瘤控制率分别为100%和92.3%。
  • 2年区域控制率和远处控制率分别为81.6%和70.3%;2年无病生存率和总生存率分别为46.1%和50.3%,中位生存37.8个月。
  • 功能性磁共振成像检测到血氧水平依赖信号平均相对下降-87.1%(P=0.05);miR.142.3p与≥3级肺毒性风险增加相关(P=0.01)。

关键数值与推荐

  • 原发肿瘤SBRT加量:中央型12 Gy分2次,周围型16 Gy分2次。
  • 同步放化疗剂量:60 Gy分30次。
  • 主要终点假设:1年原发肿瘤控制率≥90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary tumor failure is common in patients treated with chemoradiation (CRT) for locally advanced NSCLC (LA-NSCLC). Stereotactic body radiation therapy (SBRT) yields high rates of primary tumor control (PTC) in early-stage NSCLC. This trial tested an SBRT boost to the primary tumor before the start of CRT to improve PTC. METHODS AND MATERIALS: Patients with LA-NSCLC received an SBRT boost in 2 fractions (central location 12 Gy, peripheral location 16 Gy) to the primary tumor, followed by standard CRT (60 Gy in 30 fractions). The primary objective was PTC rate at 1 year, and the hypothesis was that the 1-year PTC rate would be ≥90%. Secondary objectives included objective response rate, regional and distant control, disease-free survival (DFS), and overall survival (OS). Correlative studies included functional magnetic resonance imaging and blood-based miRNA analysis. RESULTS: The study enrolled 21 patients (10 men and 11 women); the median age was 62 years (range, 52-78). The median pretreatment primary tumor size was 5.0 cm (range, 1.0-8.3). The most common nonhematologic toxicities were pneumonitis, fatigue, esophagitis/dysphagia, dyspnea, and cough. Only 1 treatment-related grade 4 nonhematologic toxicity occurred (respiratory failure/radiation pneumonitis), and no grade 5 toxicities occurred. The objective response rate at 3 and 6 months was 72.7% and 80.0%, respectively, and PTC at 1 and 2 years was 100% and 92.3%, respectively. The 2-year regional and distant control rates were 81.6% and 70.3%, respectively. Disease-free survival and overall survival at 2 years were 46.1% and 50.3%, respectively, and median survival was 37.8 months. Functional magnetic resonance imaging detected a mean relative decrease in blood oxygenation level-dependent signal of -87.1% (P = .05), and miR.142.3p was correlated with increased risk of grade ≥3 pulmonary toxicity (P = .01). CONCLUSIONS: Dose escalation to the primary tumor using upfront SBRT appears feasible and safe. PTC was high and other oncologic endpoints compared favorably to standard treatment. Functional magnetic resonance imaging suggested changes in oxygenation with the first SBRT boost dose, and miR.142.3p was correlated with pulmonary toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Williams TM, Miller E, Welliver M, et al. A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387808. doi:10.1016/j.ijrobp.2024.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。